Clinical trials: New Onset Diabetes After Transplant
Diabetes Mellitus
Comparison of Insulin Therapy in Treating Post-Transplant Diabetes
To determine if the use of insulin isophane results in improved control of blood sugars compared to the use of insulin glargine in new onset diabetes after kidney, lung, or heart transplantation (NODAT).
- Trial name
- NCT01963728
- Testing
- Insulin, Isophane, insulin glargine
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Inova Health Care Services
Post-transplant Diabetes Mellitus, New Onset Diabetes After Transplant
The POWERED Study: Prophylaxis With Metformin to Prevent PTDM
PrOphylaxis With mEtformin to pREvent PTDM: a single site, placebo controlled, double blind randomised clinical trial evaluating the effectiveness of metformin to prevent post-transplant diabetes in a cohort of patients…
- Conditions
- Post-transplant Diabetes Mellitus, New Onset Diabetes After Transplant, New Onset Diabetes After Transplantation, Kidney Transplant; Complications
- Trial name
- POWERED (NCT05240274)
- Testing
- Metformin
- Where
- United Kingdom
- Volunteers
- 60 people
- Sponsor
- Barts & The London NHS Trust
Hyperglycemia
Sensor-Augmented Insulin-Pump Therapy in New-onset Diabetes After Transplantation
The SAPT-NODAT study will test the hypotheses that intensive subcutaneous insulin treatment with short acting insulin, applied continuously through an insulin pump, (i) improves glycemic control, (ii) reduces the prevalence of…
- Trial name
- SAPT-NODAT (NCT01680185)
- Testing
- Insulin lispro, Humalog (Eli Lilly) in insulin pump, Human insulin isophane, Humulin N (Eli Lilly), Standard of care
- Where
- Austria
- Volunteers
- 85 people
- Sponsor
- Medical University of Vienna
Maintenance Liver Transplant Patients With New Onset Diabetes
Conversion From Tacrolimus to Cyclosporine Microemulsion in Liver Transplant Patients With New Onset Diabetes After the 3rd Month Post-transplant
The trial is conducted in patients who have received a liver transplant, were prescribed tacrolimus to prevent organ rejection and developed diabetes from 3 month post-transplantation onwards.
- Trial name
- NCT00171717
- Testing
- Cyclosporine - cyclosporine microemulsion
- Volunteers
- 39 people
- Sponsor
- Novartis
Kidney Transplant
Evaluation of Cyclosporine Microemulsion and Tacrolimus on the Rate of New Onset Diabetes Mellitus in Kidney Transplantation Recipients
The purpose of this study is to evaluate the impact of tacrolimus and cyclosporine microemulsion on glucose metabolism in kidney transplant recipients and the efficacy and safety in preventing organ rejection
- Trial name
- NCT00171496
- Testing
- Cyclosporine microemulsion, Tacrolimus
- Volunteers
- 693 people
- Sponsor
- Novartis
de Novo Kidney Transplantation
Study to Evaluate the Safety and Efficacy of Advagraf vs Prograf in Kidney Transplantation Patients 1 Month After the Transplantation
To investigate the efficacy, safety, and drug compliance of Advagraf® (Extended Release Tacrolimus) by comparing the Advagraf® + steroid + Mycophenolate Mofetil combined therapy and the Prograf® + steroid + Mycophenolate Mofetil…
- Trial name
- AdProCISE (NCT01742624)
- Testing
- Advagraf, Prograf, Corticosteroid
- Where
- 3 sites in South Korea
- Volunteers
- 60 people
- Sponsor
- Astellas Pharma Korea, Inc.